HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting...
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose assessment underway New program announced as HMB-003, a potent peptide plasmin...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of...
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 21, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings,...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today...
CAMBRIDGE, MA, USA & COPENHAGEN, Denmark – March 5, 2026 – Hemab Therapeutics, a late stage clinical biotechnology company developing novel prophylactic therapeutics for serious, underserved coagulation disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Consistent and robust efficacy demonstrated across bleed types, locations, and dose cohorts The weekly dosing cohort achieved an estimated 87% reduction in annualized treated bleeding rate (ATBR) Results validate potential as the first prophylactic therapy to address the heavy physical and...
$157M Series C adds leading life science investors including Sofinnova Partners, a large long-only global asset management company, a large global sovereign wealth fund, and Avoro Capital Advisors Financing readies Hemab for registration studies following successful advancement of sutacimig through...
Seasoned global market access and commercialization expert brings demonstrated track record of successful specialty medicine launches to support Hemab's multiple clinical programs in high unmet need diseases COPENHAGEN, Denmark and CAMBRIDGE, Mass., Sept....
